# DAFTAR PUSTAKA

Aghdam, S.G., Ebrazeh, M., Hemmatzadeh, M., Seyfizadeh, N., Shabgah, A.G., Azizi, G., Ebrahimi, N., Babaie, F., Mohammadi, H., 2019. The role of microRNAs in prostate cancer migration, invasion, and metastasis. *J. Cell. Physiol.* 234: 9927–9942.

Aka, A.J., Lin, S.X., 2012. Comparison of Functional Proteomic Analyses of Human breast cancer cell line T47D and MCF7. *PLos ONE.* 7. e31532.

American cancer society, 2017, Breast cancer. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf (diakses pada 10 mei 2020)

Ananta, J.S., Paulmurugan, R., Massoud, T.F., 2016. Tailored nanoparticle codelivery of antimiR-21 and antimiR-10b augments glioblastoma cell kill by temozolomide: Toward a "personalized" anti-microRNA therapy. *Mol. Pharm.* 13: 3164–3175.

Anwar, S.L., Haryono, S.J., Aryandono, T., Haryana, S.M., 2017. Micro-RNA: Biogenesis, Fungsi, dan Perannya dalam Proses Karsinogenesis dan Penatalaksanaan Kanker. Gadjah Mada University Press, Yogyakarta.

Ariff, S.A.Y., Yusoff, K., Masarudin, M.J., 2017. Encapsulation of miRNA in chitosan nanoparticles as a candidate for an anti-metastatic agent in cancer therapy. *Malaysian Appl. Biol.* 46: 165–170.

Cao Y, Tan YF, Wong YS, Liew MWJ, Venkatraman S. 2019. Recent advances in chitosan-based carriers for gene delivery. *Mar Drugs.* 17(6).

Cunningham, D., You, Z., 2015. In vitro and in vivo model systems used in prostate cancer research. *J. Biol. methods* 2: 1–14.

Chen, Y., Gao, D.Y., Huang, L., 2015. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. *Adv Drug Deliv Rev.* 81:128-141.

Chen, X., Gu, S., Chen, B.F., Shen, W.L., Yin, Z., Xu, G.W., Hu, J.J., Zhu, T., Li, G., Wan, C., Ouyang, H.W., Lee, T.L., Chan, W.Y., 2015. Nanoparticle delivery of stable miR-199a-5p agomir improves the osteogenesis of human mesenchymal stem cells via the HIF1a pathway. *Biomaterials* 53: 239–250.

Crumbaker, M., Khoja, L., Joshua, A.M., 2017. AR signaling and the PI3K pathway in prostate cancer. *Cancers (Basel).* 9: 1–15.

Debnath, S., Suresh Kumar, R., Niranjan Babu, M., 2011. Ionotropic gelation - A novel method to prepare chitosan nanoparticles. *Res. J. Pharm. Technol.* 4: 492–495.

Donzelli, S., Cioce, M., Muti, P., Strano, S., Yarden, Y., Blandino, G., 2016. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. *Semin. Cell Dev. Biol.* 50: 133–142.

Du, C., Zhang, X., Yao, M., Lv, K., Wang, J., Chen, L., Chen, Y., Wang, S., Fu, P., 2018. Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line. *Oncol. Lett.* 15: 8991–8998.

Fu, Q., Gao, Y., Yang, F., Mao, T., Sun, Z., Wang, H., Song, B., Li, X., 2018. Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT/β-catenin signaling. *Biomed. Pharmacother.* 97: 120–127.

Ganju, A., Khan, S., Hafeez, B.B., Behrman, S.W., Yallapu, M.M., Chauhan, S.C., Jaggi, M., 2017. miRNA nanotherapeutics for cancer. *Drug Discov. Today* 22: 424–432.

Gaur, S., Wen, Y., Song, J.H., Parikh, N.U., Mangala, L.S., Blessing, A.M., Ivan, C., Wu, S.Y., Varkaris, A., Shi, Y., Lopez-Berestein, G., Frigo, D.E., Sood, A.K., Gallick, G.E., 2015. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget*. 6

Genecards, 2019. Mir 106b-5p gene. https://www.genecards.org/cgi-bin/carddisp.pl?gene=MIR106B&keywords=mir,106b (diakses pada 10 mei 2010)

Genecards, 2019. PTEN gene. https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTEN&keywords=PTEN (diakses pada 24 juli 2019).

Ghaemi, Z., Soltani, B.M., Mowla, S.J., 2019. MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway. *Front.Oncol.* 9: 653.

Goto, Y., Kurozumi, A., Enokida, H., Ichikawa, T., Seki, N., 2015. Functional significance of aberrantly expressed microRNAs in prostate cancer. *Int. J. Urol.* 22: 242–252.

Guo, X., Han, T., Hu, P., Guo, X., Zhu, C., Wang, Y., Chang, S., 2018. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention. *Int. Urol. Nephrol.* 50: 2193–2200.

Guzel, E., Karatas, O.F., Semercioz, A., Ekici, S., Aykan, S., Yentur, S., Creighton, C.J., Ittmann, M., Ozen, M., 2015. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. *Int. J. Cancer* 136: 875–879.

Haldar, S., Negrini, M., Monne, M., Sabbioni, S., Croce, C.M., 1994. Down-Regulation of bcl-2 by p53 in Breast Cancer Cells. *Cancer Res.* 54: 2095–2097.

Hopkins, D.B., Hodakoski, C., Barrows, D., Mense, S., Parsons, E.R., 2014. Pten function the long and the short of it. *Biochem sci.* 39 (4): 183-190.

Hemann, M, T., Lowe, S.W., 2006. The p53-BCL2 *Connection. Cell death Filter*. 13; 1256-1259.

Howard EW, Yang X. 2018. MicroRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy. Biol Proced Online. 20(1):1–19.

Iswandana, R., Anwar, E., Jufri, M., 2013. Formulasi Nanopartikel Verapamil Hidroklorida dari Kitosan dan Natrium Tripolifosfat dengan Metode Gelasi Ionik. *J. Farm. Indones.* 6:201–210.

Jansson, M.D., Lund, A.H., 2012. MicroRNA and cancer. *Mol. Oncol.* 6: 590–610.

Karimi, M., Avci, M., Gazori, T., Hamblin, M.R., Naderi-Manesh, H., 2013. Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p-shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study. *J Nanopharm Drug Deliv.* 1: 266-278178.

Katas, H., Alpar, H.O., 2006. Development and characterization of chitosan nanoparticles for siRNA delivery. *J. Control. Release* 115: 216-225.

Kemenkes, Komite Penanggulangan Kanker Nasional. 2017. Pedoman Nasional Pelayanan Kedokteran: Kanker Payudara. Kementerian Kesehatan. Indonesia.

Li, N., Miao, Y., Shan, Y., Liu, B., Li, Y., Zhao, L., Jia, L., 2017. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. *Cell Death Dis.* 8: e2796.

Liu, Z., Jiao, Y., Wang, Y., Zhou, C., Zhang, Z., 2008. Polysaccharides-based nanoparticles as drug delivery systems. *Adv. Drug Deliv. Rev.* 60: 1650–1662.

Lin, S., Gregory, R.I., 2015. MicroRNA biogenesis pathways in cancer. *Nat. Rev. Cancer* 15: 321–333.

Lumachi F, Brunello A, Maruzzo M, Basso U, Basso S. 2013. Treatment of Estrogen Receptor-Positive Breast Cancer. Curr Med Chem. 20(5):596–604.

Luu, H.N., Lin, H.Y., Sørensen, K.D., Ogunwobi, O.O., Kumar, N., Chornokur, G., Phelan, C., Jones, D., Kidd, L.C., Batra, J., Yamoah, K., Berglund, A., Rounbehler, R.J., Yang, M., Lee, S.H., Kang, N., Kim, S.J., Park, J.Y., Di Pietro, G., 2017. miRNAs associated with prostate cancer risk and progression. *BMC Urol.* 17: 1–18.

MacGregor Schafer, J., Lee, E.S., O'Regan, R.M., Yao, K., Jordan, V.C., 2000. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. *Clin. Cancer Res.* 6: 4373–4380.

Mansouri, S., Lavigne, P., Corsi, K., Benderdour, M., Beaumont, E., Fernandes, J.C., 2004. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: Strategies to improve transfection efficacy. *Eur. J. Pharm. Biopharm.* 57: 1–8.

Mao, S., Sun, W., Kissel, T., 2010. Chitosan-based formulations for delivery of DNA and siRNA. *Adv. Drug Deliv. Rev.* 62: 12–27.

Martien, R., Adhyatmika, Irianto, I.D.K., Farida, V., Sari, D.P., 2012. Perkembangan teknologi nanopartikel sebagai sistem penghantaran obat. *Maj. Farm.* 8: 133–144.

MacGregor Schafer, J., Lee, E.S., O'Regan, R.M., Yao, K., Jordan, V.C., 2000. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. *Clin. Cancer Res.* 6: 4373–4380.

Mehlich, D., Garbicz, F., Włodarski, P.K., 2018. The emerging roles of the polycistronic miR-106b~25 cluster in cancer – A comprehensive review. *Biomed. Pharmacother.* 107: 1183–1195.

Merino, D., Lok, S.W., Visvader, J.E., Lindeman, G.J., 2016. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. *Oncogene* 35: 1877–1887.

Mohammed, M.A., Syeda, J.T.M., Wasan. K.M., Wasan, E.K., 2017. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. *Pharmaceutics*. 9:1-26.

Moi, L., Braaten, T., Khalid, A., Lund, E., Busund, L.T.J., 2019. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type results from the Norwegian women and cancer (nowac) study. *J Transl Med.* 17:334.

Mulrane, L., McGee, S.F., Gallagher, W.M., O'Connor, D.P., 2013. miRNA dysregulation in breast cancer. *Cancer Res.* 73: 6554–6562.

Nidhin, M., Indumathy, R., Sreeram, K.J., Nair, B.U., 2008. Synthesis of iron oxide nanoparticles of narrow size distribution on.pdf>. *Bull.Mater. Sci.* 31:93-96.

Nguyen, D.D., Chang, S., 2018. Development of novel therapeutic agents by inhibition of oncogenic microRNAs. *Int. J. Mol. Sci.* 19: 1–17.

Park, K., Lee, S., Kang, E., Kim, K., Choi, K., Kwon, I.C., 2009. New generation of multifunctional nanoparticles for cancer imaging and therapy. *Adv. Funct. Mater.* 19: 1553–1566.

Pellegrino, T., Sperling, R.A., Alivisatos, A.P., Parak, W.J., 2008. Gel Electrophoresis of Gold-DNA Nanoconjugates. *J. Biomed. Biotechnol.* 2007: 1-9.

Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M.P., Hobbs, R.M., *et al.,* 2010. Identification of the miR-106b~25 MicroRNA Cluster as a proto-oncogenic PTEN targeting intron that cooperates with its host gene MCM7 in transformation. *Sci Signal.* 3:117.

Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tammela, T.L.J., Visakorpi, T., 2007. MicroRNA expression profiling in prostate cancer. *Cancer Res.* 67: 6130–6135.

Rampino, A., Borgogna, M., Blasi, P., Bellich, B., Cesàro, A., 2013. Chitosan nanoparticles: Preparation, size evolution and stability. *Int. J. Pharm.* 455: 219–228.

Ragelle, H., Vandermeulen, G., Préat, V., 2013. Chitosan-based siRNA delivery systems. *J. Control. Release* 172: 207–218.

Reitan, N.K., Maurstad, G., de Lange Davies, C., Strand, S.P., 2009. Characterizing DNA condensation by structurally different chitosans of variable gene transfer efficacy. *Biomacromolecules.* 10:1508.

Rupaimoole, R., Slack, F.J., 2017. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* 16: 203–222.

Santos-Carballal, B., Aaldering, L.J., Ritzefeld, M., Pereira, S., Sewald, N., Moerschbacher, B.M., Götte, M., Goycoolea, F.M., 2015. Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Sci. Rep.* 5: 1–15.

Senthilraja, P., Kathiresan, K., 2015. In vitro cytotoxicity MTT assay in vero, HepG2 and MCF-7 cell lines study of marine yeast. *J. Appl. Pharm. Sci.* 5: 80–84.

Shah, R., Rosso, K., David Nathanson, S., 2014. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J. Clin. Oncol.* 5: 283–298.

Shenouda, S.K., Alahari, S.K., 2009. MicroRNA function in cancer: Oncogene or a tumor suppressor? *Cancer Metastasis Rev.* 28: 369–378.

Shi, Y., Paluch, B.E., Wang, X., Jiang, X., 2012. PTEN at a glance. *J. Cell Sci.* 125: 4687–4692.

Sobel, R.E., Sadar, M.D., 2005. Cell lines used in prostate cancer research: A compendium of old and new lines - Part 1. *J. Urol.* 173: 342–359.

Song, M.S., Salmena, L., Pandolfi, P.P., 2012. The functions and regulation of the PTEN tumour suppressor. *Nat. Rev. Mol. Cell Biol.* 13: 283–296.

Svoronos, A.A., Engelman, D.M., Slack, F.J., 2016. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. *Cancer Res.* 76: 3666–3670.

Teplyuk, N.M., Uhlmann, E.J., Gabriely, G., Volfovsky, N., Wang, Y., Teng, J., Karmali, P., Marcusson, E., Peter, M., Mohan, A., Kraytsberg, Y., Cialic, R., Chiocca, E.A., Godlewski, J., Tannous, B., Krichevsky, A.M., 2016. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. *EMBO Mol. Med.* 8: 268–287.

Torre, L., Rebecca Siegel, A.J., 2015. Global Cancer Facts & Figures 3rd Edition. *Am. Cancer Soc.*

Vanacore, D., Boccellino, M., Rossetti, S., Cavaliere, C., D'Aniello, C., Di Franco, R., Romano, F.J., Montanari, M., La Mantia, E., Piscitelli, R., Nocerino, F., Cappuccio, F., Grimaldi, G., Izzo, A., Castaldo, L., Pepe, M.F., Malzone, M.G., Iovane, G., Ametrano, G., Stiuso, P., Quagliuolo, L., Barberio, D., Perdonà, S., Muto, P., Montella, M., Maiolino, P., Veneziani, B.M., Botti, G., Caraglia, M., Facchini, G., 2017. Micrornas in prostate cancer: an overview. *Oncotarget* 8: 50240–50251.

Van Slooten, H.J., Van De Vijver, M.J., Van De Velde, C.J.H., Van Dierendonck, J.H., Duval, C., Pallud, C., Mandard, A.M., Delobelle-Deroide, A., 1998. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. *Br. J. Cancer* 77: 789–796.

Xu-Monette, Z.Y., Jeffrey Medeiros, L., Li, Y., Orlowski, R.Z., Andreeff, M., Bueso-Ramos, C.E., Greiner, T.C., McDonnell, T.J., Young, K.H., 2012. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. *Blood* 119: 3668–3683.

Wen, X., 2016. The PI3K AKT pathway in the pathogenesis of prostate cancer. *Front. Biosci.* 21: 1084–1091.

Wu, Y. ling, Mehew, J.W., Heckman, C.A., Arcinas, M., Boxer, L.M., 2001. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. *Oncogene* 20: 240–251.

Ysrafil, Y., Astuti, I., Anwar, S.L., Martien, R., Sumadi, F.A.N., Haryana, S.F., 2020. MicroRNA-155-5p diminishes in vitro ovarian cancer cell viability by targeting HIF1α expression. *Adv Pharm Bull*. 10 (4). 630-637.

Yu, S., Kim, T., Yoo, K.H., Kang, K, 2017. The T47D cell line is ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. *Bio.chem and biopsy resc.* 1-7.

Zhao, H., Wang, J., To, T.S., 2015. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review). *Int.J.Onc.* 47: 429-436.